Pharmaceutical

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer.

Aug 30, 2023 - 20:00
Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer.
Read the original article

Tags:

Previous Article

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

Next Article

Boston Scientific’s Farapulse System Irregular Heartbeat Treatment 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

STAT+: This chemist’s last startup sold for $4 billion....

Feb 29, 2024

Tapotoclax by Amgen for Myelodysplastic Syndrome: Likel...

Feb 8, 2024

STAT+: Republican presidential candidates spar over abortion bans

STAT+: Republican presidential candidates spar over abo...

Aug 27, 2023